Copyright: ©Author(s) 2026.
World J Psychiatry. Aug 19, 2026; 16(8): 117931
Published online Aug 19, 2026. doi: 10.5498/wjp.117931
Published online Aug 19, 2026. doi: 10.5498/wjp.117931
Table 1 General data analysis, n (%)
| Data | n | Control group (n = 66) | Observation group (n = 79) | t/Z/χ2 value | P value |
| Sex | 0.570 | 0.450 | |||
| Male | 84 | 36 (54.55) | 48 (60.76) | ||
| Female | 61 | 30 (45.45) | 31 (39.24) | ||
| Age (years) | 145 | 59.62 ± 13.00 | 59.19 ± 9.10 | 0.233 | 0.816 |
| Disease duration (months) | 145 | 7.00 (5.75, 8.00) | 7.00 (6.00, 9.00) | 0.316 | 0.752 |
| Tumor diameter (cm) | 145 | 4.06 ± 1.42 | 4.26 ± 1.73 | 0.751 | 0.454 |
| Lesion location | 0.469 | 0.494 | |||
| Left hemicolon | 68 | 33 (50.00) | 35 (44.30) | ||
| Right hemicolon | 77 | 33 (50.00) | 44 (55.70) | ||
| TNM staging | 1.293 | 0.255 | |||
| II | 50 | 26 (39.39) | 24 (30.38) | ||
| III | 95 | 40 (60.61) | 55 (69.62) | ||
| Chemotherapy regimen | 0.425 | 0.514 | |||
| mFOLFOX6 | 77 | 37 (56.06) | 40 (50.63) | ||
| FOLFIRI | 68 | 29 (43.94) | 39 (49.37) | ||
| Educational level | 0.055 | 0.815 | |||
| Below senior high school | 60 | 28 (42.42) | 32 (40.51) | ||
| Senior high school or above | 85 | 38 (57.58) | 47 (59.49) |
Table 2 Short-term efficacy, n (%)
| Therapeutic effectiveness | Control group (n = 66) | Observation group (n = 79) | χ2 value | P value |
| Complete remission | 10 (15.15) | 18 (22.78) | ||
| Partial remission | 30 (45.45) | 39 (49.37) | ||
| Stable disease | 20 (30.30) | 17 (21.52) | ||
| Progressive disease | 6 (9.09) | 5 (6.33) | ||
| Overall response | 40 (60.61) | 57 (72.15) | 2.165 | 0.141 |
Table 3 Clinical safety evaluation, n (%)
| Safety | Control group (n = 66) | Observation group (n = 79) | χ2 value | P value |
| Mucositis | 2 (3.03) | 2 (2.53) | 0.033 | 0.855 |
| Diarrhea | 6 (9.09) | 4 (5.06) | 0.908 | 0.341 |
| Alopecia | 8 (12.12) | 7 (8.86) | 0.412 | 0.521 |
| Anorexia | 13 (19.70) | 10 (12.66) | 1.335 | 0.248 |
| Nausea | 2 (3.03) | 4 (5.06) | 0.375 | 0.541 |
| Insomnia | 1 (1.52) | 3 (3.80) | 0.698 | 0.403 |
| Sexual dysfunction | 0 (0.00) | 0 (0.00) | - | - |
| Agitation | 0 (0.00) | 0 (0.00) | - | - |
Table 4 Quality of life assessment
| EORTC QLQ-C30 (points) | Control group (n = 66) | Observation group (n = 79) | Z/t value | P value | |
| Physical function | Before | 52.00 (50.00, 55.25) | 53.00 (49.00, 58.00) | -1.082 | 0.279 |
| After | 58.50 (52.75, 61.00) | 64.00 (59.00, 70.00) | -5.788 | < 0.001 | |
| Role function | Before | 50.92 ± 5.08 | 50.14 ± 5.70 | 0.862 | 0.390 |
| After | 60.12 ± 5.06 | 67.33 ± 7.64 | 6.557 | < 0.001 | |
| Emotional function | Before | 55.64 ± 5.77 | 54.96 ± 6.15 | 0.682 | 0.496 |
| After | 60.95 ± 5.27 | 63.97 ± 6.46 | 3.044 | 0.003 | |
| Cognitive function | Before | 53.95 ± 4.92 | 52.71 ± 6.56 | 1.266 | 0.207 |
| After | 60.02 ± 5.94 | 64.32 ± 7.05 | 3.925 | < 0.001 | |
| Social function | Before | 58.05 ± 4.97 | 59.70 ± 5.84 | 1.812 | 0.072 |
| After | 64.53 ± 6.41 | 69.46 ± 6.64 | 4.523 | < 0.001 | |
Table 5 Mood improvement-associated determinants in chemotherapy-managed colon cancer patients (univariate screening), n (%)
| Data | n | Ineffective group (n = 34) | Effective group (n = 111) | χ2 value | P value |
| Sex | 2.154 | 0.142 | |||
| Male | 84 | 16 (47.06) | 68 (61.26) | ||
| Female | 61 | 18 (52.94) | 43 (38.74) | ||
| Age (years) | 2.605 | 0.107 | |||
| < 60 | 73 | 13 (38.24) | 60 (54.05) | ||
| ≥ 60 | 72 | 21 (61.76) | 51 (45.95) | ||
| Disease duration (months) | 0.273 | 0.601 | |||
| < 7 | 48 | 10 (29.41) | 38 (34.23) | ||
| ≥ 7 | 97 | 24 (70.59) | 73 (65.77) | ||
| Tumor diameter (cm) | 3.664 | 0.056 | |||
| < 4 | 72 | 12 (35.29) | 60 (54.05) | ||
| ≥ 4 | 73 | 22 (64.71) | 51 (45.95) | ||
| Lesion location | 0.584 | 0.445 | |||
| Left hemicolon | 68 | 14 (41.18) | 54 (48.65) | ||
| Right hemicolon | 77 | 20 (58.82) | 57 (51.35) | ||
| TNM staging | 0.089 | 0.765 | |||
| II | 50 | 11 (32.35) | 39 (35.14) | ||
| III | 95 | 23 (67.65) | 72 (64.86) | ||
| Chemotherapy regimen | 0.584 | 0.445 | |||
| mFOLFOX6 | 77 | 20 (58.82) | 57 (51.35) | ||
| FOLFIRI | 68 | 14 (41.18) | 54 (48.65) | ||
| Educational level | 0.591 | 0.442 | |||
| Below senior high school | 60 | 16 (47.06) | 44 (39.64) | ||
| Senior high school or above | 85 | 18 (52.94) | 67 (60.36) | ||
| 5-HT (ng/mL) | 6.555 | 0.011 | |||
| < 12 | 62 | 21 (61.76) | 41 (36.94) | ||
| ≥ 12 | 83 | 13 (38.24) | 70 (63.06) | ||
| NE (pg/mL) | 1.078 | 0.299 | |||
| < 330 | 71 | 14 (41.18) | 57 (51.35) | ||
| ≥ 330 | 74 | 20 (58.82) | 54 (48.65) | ||
| Treatment modality | 28.337 | < 0.001 | |||
| Psychological intervention + fluoxetine | 79 | 5 (14.71) | 74 (66.67) | ||
| Psychological intervention | 66 | 29 (85.29) | 37 (33.33) |
Table 6 Factors impacting mood improvement in chemotherapy-managed colon cancer patients (multivariate analysis)
| Variable | β | SE | Wald | P value | OR | 95%CI |
| 5-HT (ng/mL) | -0.765 | 0.446 | 2.946 | 0.086 | 0.465 | 0.194-1.115 |
| Treatment modality | 2.357 | 0.529 | 19.865 | < 0.001 | 10.564 | 3.746-29.788 |
- Citation: Zhu XX, Zhao S, Xu Q, Tang R, Xu LX, Zhou YJ, Zhang DY. Fluoxetine plus psychological intervention for chemotherapy-managed colon cancer patients: Impact on mood and influencing factors. World J Psychiatry 2026; 16(8): 117931
- URL: https://www.wjgnet.com/2220-3206/full/v16/i8/117931.htm
- DOI: https://dx.doi.org/10.5498/wjp.117931